Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Executive Summary

Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition

You may also be interested in...



Sanofi-Aventis Offer To Buy Genzyme Seen As Starting Point For Long Negotiation

French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.

Sanofi Sues FDA, Claiming Agency Exceeded Its Authority In Approving Enoxaparin

Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.

Sandoz Launches Generic Lovenox

Sandoz has a monopoly on the generic enoxaparin market for now, but Teva insists its ANDA is progressing at FDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS052490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel